clinical trial · NCT05707377
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
BeOne Medicines·phase3·active not recruiting·n = 178
Primary Membranous NephropathyZanubrutinibTacrolimus
brief summary
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
started
Apr 17, 2023
primary completion
Oct 1, 2027
completion
Oct 1, 2027
last updated
Jul 23, 2026
detailed description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
official title
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol